Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$53.39 USD

53.39
800,724

-2.28 (-4.09%)

Updated Feb 8, 2023 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.28%
2Buy17.83%
3Hold9.19%
4Sell5.00%
5Strong Sell2.16%
S&P50010.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for CRSP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

CRISPR Therapeutics AG [CRSP]

Reports for Purchase

Showing records 1 - 20 ( 196 total )

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 1

01/27/2023

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 2

01/22/2023

Industry Report

Pages: 5

Biotech Coverage: 2023 Anticipated Drug Approvals and Data Releases

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 5.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 3

01/02/2023

Company Report

Pages: 8

2023 Valuation Fine-Tuning and Catalyst Outlook

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 12.50

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 4

12/27/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 5

12/12/2022

Company Report

Pages: 22

CTX110 CARBON Study Data at ASH; Supports Our Outlook

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 35.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 6

11/24/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 7

11/16/2022

Industry Report

Pages: 5

Biotech Coverage: Upcoming Data Releases, Medical Meetings, by YE 2022

Provider: Brookline Capital Markets

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 8

11/10/2022

Company Report

Pages: 19

COBALT-RCC Study for CTX130 Presented at SITC; Supports Our Outlook

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 25.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 9

11/09/2022

Daily Note

Pages: 13

SITC Abstracts Part II

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 10

11/06/2022

Company Report

Pages: 19

Updated CTX110 CARBON Data in ASH Abstract; Supports Our Outlook

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 25.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 11

11/02/2022

Company Report

Pages: 7

3Q22: BLA Rolling Submission Begins This Month

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 12.50

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 12

11/02/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 13

11/01/2022

Company Report

Pages: 12

Reports Q3 2022; Clinical Programs On-track; Strong Cash Position

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 12.50

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 14

11/01/2022

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 15

10/10/2022

Industry Report

Pages: 4

Biotechnology Coverage: Upcoming Data Releases, Medical Meetings, and FDA-filings by YE 2022

Provider: Brookline Capital Markets

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 16

10/10/2022

Industry Report

Pages: 4

Correction - Biotech Coverage: Upcoming Data Releases, Medical Meetings, FDA-filings by YE 2022

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 5.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 17

10/07/2022

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 18

10/05/2022

Industry Report

Pages: 6

SITC 2022 Abstract Titles Released

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 19

09/28/2022

Company Report

Pages: 17

RMAT Designation for CTX130 in Rare Forms of CTCL; Potential Upside to Our Outlook

Provider: Brookline Capital Markets

Analyst: CANN L

Price: 25.00

Research Provided by a Third Party

Company: CRISPR Therapeutics AG

Industry: Medical - Biomedical and Genetics

Record: 20

09/28/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party